CNBioXYZ
@cnbio.xyz
CBX (China Biotech XYZ) – Expert pharma intelligence for strategic decisions. https://cnbio.xyz
Regeneron Pharmaceuticals has discontinued the Phase 2 NATRIX-SBP study (NCT06833190) evaluating REGN5381 in uncontrolled hypertension. The trial enrolled 34 pt before termination.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit.
October 24, 2025 at 9:48 AM
Regeneron Pharmaceuticals has discontinued the Phase 2 NATRIX-SBP study (NCT06833190) evaluating REGN5381 in uncontrolled hypertension. The trial enrolled 34 pt before termination.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit.
Betta Pharma Files for Hong Kong IPO, Valued at RMB 24.5B on SZSE
October 14, 2025 at 3:27 AM
Betta Pharma Files for Hong Kong IPO, Valued at RMB 24.5B on SZSE
Sirius Therapeutics Files for Hong Kong IPO, With Two siRNA Phase 2 Assets Targeting FXI and Lp(a).
October 14, 2025 at 3:21 AM
Sirius Therapeutics Files for Hong Kong IPO, With Two siRNA Phase 2 Assets Targeting FXI and Lp(a).
CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028. Tables might turn — will CTTQ's Anlotinib be next? $HCM $TAK
July 25, 2025 at 3:00 AM
CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028. Tables might turn — will CTTQ's Anlotinib be next? $HCM $TAK
BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns.
July 22, 2025 at 3:14 AM
BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns.
BMS has submitted its first IND application in China for BMS-986340, an investigational anti-CCR8 monoclonal antibody. $BMY $ZLAB $ONC
July 22, 2025 at 1:09 AM
BMS has submitted its first IND application in China for BMS-986340, an investigational anti-CCR8 monoclonal antibody. $BMY $ZLAB $ONC
Puhe Biopharma Submits IND Application in China for WRN Inhibitor PH027 Targeting MSI-H Tumors. $NVS $GSK $RHHBY
July 17, 2025 at 1:57 AM
Puhe Biopharma Submits IND Application in China for WRN Inhibitor PH027 Targeting MSI-H Tumors. $NVS $GSK $RHHBY
Hemay Pharmaceutical Files for Hong Kong IPO After 3.9B RMB Valuation in December Round
May 30, 2025 at 4:35 AM
Hemay Pharmaceutical Files for Hong Kong IPO After 3.9B RMB Valuation in December Round
Beigene temporarily halted the first-in-human trial of BGB-A3055 (#CCR8) due to a sponsor decision, not a change in the safety or benefit-risk balance. Last November, Zai Lab also halted its anti-CCR8 antibody ZL-1218 due to safety reasons.
May 15, 2025 at 6:06 AM
Beigene temporarily halted the first-in-human trial of BGB-A3055 (#CCR8) due to a sponsor decision, not a change in the safety or benefit-risk balance. Last November, Zai Lab also halted its anti-CCR8 antibody ZL-1218 due to safety reasons.
Insilico Medicine files for a Hong Kong IPO, with its latest post-money valuation at $1.331 billion.
May 8, 2025 at 11:48 PM
Insilico Medicine files for a Hong Kong IPO, with its latest post-money valuation at $1.331 billion.
Suzhou Ribo Life Science (瑞博生物) files for a Hong Kong IPO with a post-Series E2 financing valuation of 4.8 billion RMB.
April 26, 2025 at 12:13 PM
Suzhou Ribo Life Science (瑞博生物) files for a Hong Kong IPO with a post-Series E2 financing valuation of 4.8 billion RMB.
The next generation anti-nectin-4 ADC LY4052031 study (NCT06465069) is on hold because Eli Lilly called it off. It's about advanced urothelial or other solid tumors.
April 24, 2025 at 3:06 PM
The next generation anti-nectin-4 ADC LY4052031 study (NCT06465069) is on hold because Eli Lilly called it off. It's about advanced urothelial or other solid tumors.
Live now meetings.asco.org/abstracts-pr...
April 23, 2025 at 2:54 PM
Live now meetings.asco.org/abstracts-pr...
#ASCO25 release abstract titles today. Meeting.asco.org
Program Guide – ASCO Meeting Program Guide
Meeting.asco.org
April 23, 2025 at 2:46 AM
#ASCO25 release abstract titles today. Meeting.asco.org
MapKure, a joint venture between SpringWorks and BeiGene, has officially terminated the development of its RAF dimer inhibitor BGB-3245 (brimarafenib) following a funding halt driven by strategic business considerations. $SWTX $ONC
April 21, 2025 at 2:07 PM
MapKure, a joint venture between SpringWorks and BeiGene, has officially terminated the development of its RAF dimer inhibitor BGB-3245 (brimarafenib) following a funding halt driven by strategic business considerations. $SWTX $ONC
Merck has suspended the Phase 1 trial of #M5542, a CD80, CD86, and OX40L antagonist developed for autoimmune diseases, citing sponsor-related reasons. #NCT06577337
January 17, 2025 at 10:21 AM
Merck has suspended the Phase 1 trial of #M5542, a CD80, CD86, and OX40L antagonist developed for autoimmune diseases, citing sponsor-related reasons. #NCT06577337
Mabwell (Shanghai) Bioscience has applied for an IPO in Hong Kong.
January 7, 2025 at 1:50 AM
Mabwell (Shanghai) Bioscience has applied for an IPO in Hong Kong.
Hengrui Pharmaceuticals files for the Hong Kong IPO.
January 7, 2025 at 1:49 AM
Hengrui Pharmaceuticals files for the Hong Kong IPO.